世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

プライマリケア向けPOC診断薬の市場規模、シェア、動向分析レポート:製品別(グルコース検査、脂質検査、薬物乱用検査)、エンドユース別(薬局・小売クリニック、医師オフィス)、地域別、セグメント別予測、2023年~2030年


Primary Care POC Diagnostics Market Size, Share & Trends Analysis Report By Product (Glucose Testing, Lipid Testing, Drug Abuse Testing), By End-use (Pharmacy & Retail Clinics, Physician Office), By Region, And Segment Forecasts, 2023 - 2030

プライマリケアPOC診断市場の成長と動向 Grand View Research, Inc.の新しいレポートによると、プライマリケアPOC診断の世界市場規模は2030年までに261億7000万米ドルに達すると予測されており、予測期間中のC... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2023年10月23日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
192 英語

本レポートは受注生産のため、ご納品のお時間をいただく場合がございます。


 

サマリー

プライマリケアPOC診断市場の成長と動向

Grand View Research, Inc.の新しいレポートによると、プライマリケアPOC診断の世界市場規模は2030年までに261億7000万米ドルに達すると予測されており、予測期間中のCAGRは6.5%を記録している。柔軟で先進的な中核分子ラボは、多くの一般的なターゲットのスクリーニングを病院のレセプションルームや医師のオフィスに移すために、POC検査の使用を受け入れ、サポートしている。

2014年にAmerican Journal of Clinical Pathologyが実施した研究によると、POC検査は、患者のフォローアップコールと手紙をそれぞれ85.0%と89.0%削減し、フォローアップ受診を61.0%削減することにより、メーカーの臨床業務を改善することが判明した。また、検査オーダー数が21.0%減少したことも確認された。

さらに、1988年臨床検査改善法(CLIA)の下で免除ステータスを受ける検査数の増加が、市場の成長を促進すると予想される。患者1人当たり約12~15米ドルのコスト削減と約50.0%のフォローアップ検査削減により、研究者やメーカーはますますこれらの検査を推奨するようになっている。しかし、異なる検査法とその使用領域には大きな重複がある。例えば、グルコース測定パネルや迅速国際標準化比検査は、もともと自己検査用であったが、現在では病院や一次検査で使用されている。

プライマリケアPOC診断市場レポートハイライト

- 感染症分野は2022年に26.4%の最大市場シェアを占めたが、これは感染症の流行の増加、迅速かつ正確な診断への需要、POC検査の利点に対する認識の高まりによるものである。

- 定期検診の一環として脂質検査を実施する外来患者の増加により、脂質検査の市場導入率が積極的に高まると予想され、製品別市場全体でも突出した地位を占める。

- 最終用途の面では、研究機関やバイオテクノロジー企業による先進的でより正確なPOC検査キットの共同研究が医院部門を促進すると思われる一方、政府のイニシアティブやプライマリケア施設の拡張プロジェクトが非診療所部門を後押しすると思われる。

- 北米のプライマリ・ケアPOC診断市場は、世界の他の地域よりも発展している。同地域は、革新的で先進的なPOC診断製品が複数存在すること、プライマリ在宅医療や補助医療におけるPOC診断に対する認識と需要が高まっていることが背景にある。

- 米国市場では、在宅医療、在宅検査、モニタリング機器への患者の関与の増加へのシフトが見られる。さらに、デジタル化、EHR、遠隔医療、モニタリングデータのウェブ対応ソリューションが米国で加速しており、成長を牽引している。

ページTOPに戻る


目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. End use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. End use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Primary Care POC Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Primary Care POC Diagnostics Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Primary Care POC Diagnostics: Product Estimates & Trend Analysis
4.1. Primary Care POC Diagnostics Market: Key Takeaways
4.2. Primary Care POC Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Glucose Testing
4.3.1. Glucose Testing market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Hb1Ac Testing
4.4.1. Hb1Ac testing market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. 4.5. Autoimmune Disease
4.5.1. Autoimmune Disease market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Coagulation
4.6.1. Coagulation market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Fertility
4.7.1. Fertility market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. Infectious Diseases
4.8.1. Infectious diseases market estimates and forecasts, 2018 to 2030 (USD Million)
4.9. Cardiac Markers
4.9.1. Cardiac markers market estimates and forecasts, 2018 to 2030 (USD Million)
4.10. Thyroid Stimulating Hormone
4.10.1. Thyroid stimulating hormone market estimates and forecasts, 2018 to 2030 (USD Million)
4.11. Hematology
4.11.1. Hematology market estimates and forecasts, 2018 to 2030 (USD Million)
4.12. Primary Care Systems
4.12.1. Primary care systems market estimates and forecasts, 2018 to 2030 (USD Million)
4.13. Decentralized Clinical Chemistry
4.13.1. Decentralized clinical chemistry market estimates and forecasts, 2018 to 2030 (USD Million)
4.14. Feces
4.14.1. Feces market estimates and forecasts, 2018 to 2030 (USD Million)
4.15. Lipid Testing
4.15.1. Lipid testing market estimates and forecasts, 2018 to 2030 (USD Million)
4.16. Cancer Markers
4.16.1. Cancer markers market estimates and forecasts, 2018 to 2030 (USD Million)
4.17. Blood Gas/Electrolytes
4.17.1. Blood gas/electrolytes market estimates and forecasts, 2018 to 2030 (USD Million)
4.18. Ambulatory Chemistry
4.18.1. Ambulatory chemistry market estimates and forecasts, 2018 to 2030 (USD Million)
4.19. Drug Abuse Testing
4.19.1. Drug abuse testing market estimates and forecasts, 2018 to 2030 (USD Million)
4.20. Urinalysis
4.20.1. Urinalysis market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Primary Care POC Diagnostics: End Use Estimates & Trend Analysis
5.1. Primary Care POC Diagnostics Market: Key Takeaways
5.2. Primary Care POC Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Pharmacy & Retail Clinics
5.3.1. Pharmacy & Retail Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Physician office
5.4.1. Physician office market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Urgent Care Clinics
5.5.1. Urgent care clinics market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Non-practice Clinics
5.6.1. Non-practice clinics market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Primary Care POC Diagnostics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Primary Care POC Diagnostics Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. F Hoffmann-La Roche Ltd.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Danaher
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Abbott
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Siemens Healthineers
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. bioMerieux SA
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Abaxis
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. QIAGEN
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Johnson & Johnson Services, Inc.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Nova Biomedical
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Instrumentation Laboratory
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Trividia Health, Inc.
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. OraSure Technologies, Inc.
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Quidel Corporation
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. Trinity Biotech
7.2.14.1. Company overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives
7.2.15. Sekisui Diagnostics
7.2.15.1. Company overview
7.2.15.2. Financial performance
7.2.15.3. Product benchmarking
7.2.15.4. Strategic initiatives
7.2.16. BD
7.2.16.1. Company overview
7.2.16.2. Financial performance
7.2.16.3. Product benchmarking
7.2.16.4. Strategic initiatives

 

ページTOPに戻る


 

Summary

Primary Care POC Diagnostics Market Growth & Trends

The global primary care POC diagnostics market size is expected to reach USD 26.17 billion by 2030, according to a new report by Grand View Research, Inc., registering a 6.5% CAGR during the forecast period. Flexible and forward-thinking core molecular labs have been embracing and supporting the use of POC tests to move screening of many common targets to hospital receiving rooms and physicians’ offices.

As per a study conducted by the American Journal of Clinical Pathology in 2014, it was found that POC testing improved clinical operations for manufacturers by reducing follow-up calls and letters of patients by 85.0% and 89.0%, respectively, and reducing their follow-up visits by 61.0%. It was also observed that the number of tests ordered decreased by 21.0%.

Furthermore, rise in the number of tests receiving a waived status under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) is anticipated to aid market growth. Researchers and manufacturers are increasingly recommending these tests owing to cost reduction of about USD 12-15 per patient and reduction in follow up tests by about 50.0%. However, there is a massive overlap between different methods and their areas of usage. For instance, panels to measure glucose and quick international normalized ratio tests were originally meant for self-testing but are now used in hospitals and primary settings instead.

Primary Care POC Diagnostics Market Report Highlights

• The infectious disease segment held the largest market share at 26.4% in 2022, owing to the increased prevalence of infectious diseases, demand for quick and precise diagnosis, and the growing awareness of the benefits of POC testing.

• Increase in out-patient practices for lipid testing as part of a routine checkup is expected to positively enhance the adoption rate of lipid testing in the market, giving it a prominent spot in the overall market by product

• In terms of end use, while collaborative research for advanced and more accurate POC testing kits by research institutes and biotech firms is likely to facilitate the physicians’ office segment, government initiatives and projects to extend primary care facilities will boost the non-practice clinics segment

• The North America primary care POC diagnostics market is more developed compared to the rest of the world. The regional segment is fueled by availability of several innovative and advanced POC diagnostic products and growing awareness and demand for point-of-care diagnostics in primary home healthcare and assisted healthcare

• The U.S. market is witnessing a shift toward increasing patient involvement in home care, home-based tests, and monitoring instruments. In addition, digitalization, EHR, telemedicine, and web-enabled solutions of monitoring data are gaining pace in U.S., thereby driving its growth



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. End use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. End use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Primary Care POC Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Primary Care POC Diagnostics Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Primary Care POC Diagnostics: Product Estimates & Trend Analysis
4.1. Primary Care POC Diagnostics Market: Key Takeaways
4.2. Primary Care POC Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Glucose Testing
4.3.1. Glucose Testing market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Hb1Ac Testing
4.4.1. Hb1Ac testing market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. 4.5. Autoimmune Disease
4.5.1. Autoimmune Disease market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Coagulation
4.6.1. Coagulation market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Fertility
4.7.1. Fertility market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. Infectious Diseases
4.8.1. Infectious diseases market estimates and forecasts, 2018 to 2030 (USD Million)
4.9. Cardiac Markers
4.9.1. Cardiac markers market estimates and forecasts, 2018 to 2030 (USD Million)
4.10. Thyroid Stimulating Hormone
4.10.1. Thyroid stimulating hormone market estimates and forecasts, 2018 to 2030 (USD Million)
4.11. Hematology
4.11.1. Hematology market estimates and forecasts, 2018 to 2030 (USD Million)
4.12. Primary Care Systems
4.12.1. Primary care systems market estimates and forecasts, 2018 to 2030 (USD Million)
4.13. Decentralized Clinical Chemistry
4.13.1. Decentralized clinical chemistry market estimates and forecasts, 2018 to 2030 (USD Million)
4.14. Feces
4.14.1. Feces market estimates and forecasts, 2018 to 2030 (USD Million)
4.15. Lipid Testing
4.15.1. Lipid testing market estimates and forecasts, 2018 to 2030 (USD Million)
4.16. Cancer Markers
4.16.1. Cancer markers market estimates and forecasts, 2018 to 2030 (USD Million)
4.17. Blood Gas/Electrolytes
4.17.1. Blood gas/electrolytes market estimates and forecasts, 2018 to 2030 (USD Million)
4.18. Ambulatory Chemistry
4.18.1. Ambulatory chemistry market estimates and forecasts, 2018 to 2030 (USD Million)
4.19. Drug Abuse Testing
4.19.1. Drug abuse testing market estimates and forecasts, 2018 to 2030 (USD Million)
4.20. Urinalysis
4.20.1. Urinalysis market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Primary Care POC Diagnostics: End Use Estimates & Trend Analysis
5.1. Primary Care POC Diagnostics Market: Key Takeaways
5.2. Primary Care POC Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Pharmacy & Retail Clinics
5.3.1. Pharmacy & Retail Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Physician office
5.4.1. Physician office market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Urgent Care Clinics
5.5.1. Urgent care clinics market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Non-practice Clinics
5.6.1. Non-practice clinics market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Primary Care POC Diagnostics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Primary Care POC Diagnostics Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. F Hoffmann-La Roche Ltd.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Danaher
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Abbott
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Siemens Healthineers
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. bioMerieux SA
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Abaxis
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. QIAGEN
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Johnson & Johnson Services, Inc.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Nova Biomedical
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Instrumentation Laboratory
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Trividia Health, Inc.
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. OraSure Technologies, Inc.
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Quidel Corporation
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. Trinity Biotech
7.2.14.1. Company overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives
7.2.15. Sekisui Diagnostics
7.2.15.1. Company overview
7.2.15.2. Financial performance
7.2.15.3. Product benchmarking
7.2.15.4. Strategic initiatives
7.2.16. BD
7.2.16.1. Company overview
7.2.16.2. Financial performance
7.2.16.3. Product benchmarking
7.2.16.4. Strategic initiatives

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

Grand View Research社の臨床検査分野での最新刊レポート

本レポートと同じKEY WORD(primary care)の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/20 10:28

158.95 円

165.20 円

201.28 円

ページTOPに戻る